At the ACC, 24-month data for the Symplicity renal denervation system showed that patients (number = 40) initially randomised to the intervention, compared with their baseline levels, had a sustained sustained significant drop in blood pressure (-29/-10 mmHg; p<0.01]).
According to a Medtronic press release, the 26 patients in the control group who crossed-over and received renal denervation following assessment of the six-month primary endpoint (crossover group) had an average blood pressure reduction of –35/-13 mmHg [p<0.01] at 24 months.These 24-month average blood pressure reductions demonstrate preservation of the blood pressure reduction for both groups that were previously reported at six, 12, and 18-month follow-up. There were no device-related serious adverse events, no late vascular complications, and no significant decline in kidney function compared to pre-procedure values reported out to 24 months post-procedure.
Professor Henry Krum, chair of medical therapeutics, professor of medicine and director of the Monash Centre of Cardiovascular Research and Education in Therapeutics, Melbourne, Australia who presented the data today at ACC.13, said: “These latest data add to the growing body of evidence demonstrating consistent blood pressure reduction with the Symplicity system and underscore its potential as an option for us to help our medication-refractory patients achieve better blood pressure control.”
At 24 months, pulse pressure improved significantly for patients in this analysis following treatment with the Symplicity system (-18.5 mm Hg from baseline for the initial treatment group [p<0.01]; and -22.5 mmHg from baseline for the crossover group [p<0.01]).